Implementation of enhanced recovery protocol did not increase rates of acute kidney injury in open gynecologic oncology surgery: A single-institution experience
Brandon P. Maddy , Kristin M. Tischer , Michaela E. McGree , Angela J. Fought , Sean C. Dowdy , Gretchen E. Glaser
{"title":"Implementation of enhanced recovery protocol did not increase rates of acute kidney injury in open gynecologic oncology surgery: A single-institution experience","authors":"Brandon P. Maddy , Kristin M. Tischer , Michaela E. McGree , Angela J. Fought , Sean C. Dowdy , Gretchen E. Glaser","doi":"10.1016/j.ygyno.2024.12.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To compare the incidence of acute kidney injury (AKI) among patients undergoing gynecologic surgery before and after implementing an Enhanced Recovery After Surgery (ERAS) pathway.</div></div><div><h3>Methods</h3><div>We conducted a retrospective review of medical records from Mayo Clinic during three time periods when ERAS was used, focusing on patients who underwent open gynecologic surgery. AKI was defined using Kidney Disease Improving Global Outcomes (KDIGO) criteria. We used inverse-probability of treatment weighting (IPTW) to adjust for baseline covariates between pre-ERAS (135 patients) and post-ERAS (486 patients) cohorts. Statistical comparisons were made using <em>t</em>-test, Wilcoxon rank-sum, chi-square or Fisher's exact test, and univariate logistic regression with odds ratio (OR) and 95 % confidence interval (CI).</div></div><div><h3>Results</h3><div>Pre-IPTW, the AKI incidence was similar between cohorts (10.4 % vs 8.4 %, <em>p</em> = 0.48), and the odds of AKI for post-ERAS patients compared to pre-ERAS was not significant (OR 0.80, 95 % CI 0.42–1.51). After IPTW-adjustment, the AKI incidence remained comparable (10.3 % vs 8.1 %, <em>p</em> = 0.41), with the odds ratio unchanged (OR 0.76, 95 % CI 0.40–1.45). AKI patients were older (mean 67.0 vs 62.4 years, <em>p</em> < 0.01), had higher ASA scores (61.8 % vs 45.2 %, <em>p</em> = 0.02), lower preoperative hemoglobin (median 10.8 vs 12.5 g/dL, <em>p</em> < 0.01), longer surgeries (median 331 vs 222 min, <em>p</em> < 0.01), greater intraoperative blood loss (median 800 vs 500 mL, <em>p</em> < 0.01), more transfusions (56.4 % vs 29.3 %, p < 0.01), and higher fluid volumes (median 5750 vs 4165 mL, p < 0.01).</div></div><div><h3>Conclusion</h3><div>The ERAS pathway did not significantly impact AKI incidence in gynecologic surgery patients. AKI remains associated with increased postoperative complications, highlighting the need for improved risk prediction and preventive strategies.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"Pages 181-188"},"PeriodicalIF":4.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0090825824012228","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To compare the incidence of acute kidney injury (AKI) among patients undergoing gynecologic surgery before and after implementing an Enhanced Recovery After Surgery (ERAS) pathway.
Methods
We conducted a retrospective review of medical records from Mayo Clinic during three time periods when ERAS was used, focusing on patients who underwent open gynecologic surgery. AKI was defined using Kidney Disease Improving Global Outcomes (KDIGO) criteria. We used inverse-probability of treatment weighting (IPTW) to adjust for baseline covariates between pre-ERAS (135 patients) and post-ERAS (486 patients) cohorts. Statistical comparisons were made using t-test, Wilcoxon rank-sum, chi-square or Fisher's exact test, and univariate logistic regression with odds ratio (OR) and 95 % confidence interval (CI).
Results
Pre-IPTW, the AKI incidence was similar between cohorts (10.4 % vs 8.4 %, p = 0.48), and the odds of AKI for post-ERAS patients compared to pre-ERAS was not significant (OR 0.80, 95 % CI 0.42–1.51). After IPTW-adjustment, the AKI incidence remained comparable (10.3 % vs 8.1 %, p = 0.41), with the odds ratio unchanged (OR 0.76, 95 % CI 0.40–1.45). AKI patients were older (mean 67.0 vs 62.4 years, p < 0.01), had higher ASA scores (61.8 % vs 45.2 %, p = 0.02), lower preoperative hemoglobin (median 10.8 vs 12.5 g/dL, p < 0.01), longer surgeries (median 331 vs 222 min, p < 0.01), greater intraoperative blood loss (median 800 vs 500 mL, p < 0.01), more transfusions (56.4 % vs 29.3 %, p < 0.01), and higher fluid volumes (median 5750 vs 4165 mL, p < 0.01).
Conclusion
The ERAS pathway did not significantly impact AKI incidence in gynecologic surgery patients. AKI remains associated with increased postoperative complications, highlighting the need for improved risk prediction and preventive strategies.
目的:比较实施ERAS (Enhanced Recovery after surgery)途径前后妇科手术患者急性肾损伤(AKI)的发生率。方法:我们对梅奥诊所使用ERAS的三个时期的医疗记录进行了回顾性分析,重点是接受开放式妇科手术的患者。AKI的定义采用肾脏疾病改善全球预后(KDIGO)标准。我们使用治疗加权逆概率(IPTW)来调整eras前(135例)和eras后(486例)队列之间的基线协变量。统计学比较采用t检验、Wilcoxon秩和检验、卡方检验或Fisher精确检验,采用优势比(or)和95%置信区间(CI)进行单因素logistic回归。结果:iptw前,各队列间AKI发生率相似(10.4% vs 8.4%, p = 0.48), eras后患者与eras前患者相比AKI的发生率无显著性差异(OR 0.80, 95% CI 0.42-1.51)。调整iptwt后,AKI发生率保持可比性(10.3% vs 8.1%, p = 0.41),优势比不变(OR 0.76, 95% CI 0.40-1.45)。AKI患者年龄较大(平均67.0岁vs 62.4岁)。结论:ERAS通路对妇科手术患者AKI发生率无显著影响。AKI仍然与术后并发症的增加有关,这突出了改进风险预测和预防策略的必要性。
期刊介绍:
Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published.
Research Areas Include:
• Cell and molecular biology
• Chemotherapy
• Cytology
• Endocrinology
• Epidemiology
• Genetics
• Gynecologic surgery
• Immunology
• Pathology
• Radiotherapy